Protein A Affinity IgG Capture Followed by AdvanceBio SEC Aggregation Analysis

Significance of the Topic

The structural integrity and aggregation profile of monoclonal antibodies are critical quality attributes in biotherapeutic development. Aggregates can affect safety, efficacy, and immunogenicity, making rapid and accurate aggregate quantification essential for R&D, process monitoring, and quality control.

Objectives and Study Overview

This study presents a two-dimensional liquid chromatography (2D-LC) workflow that integrates Protein A affinity capture with size exclusion chromatography (SEC) for comprehensive IgG titer and aggregation analysis in a single injection. The approach aims to eliminate fraction collection, reduce sample handling, and enhance throughput.

Instrumentation Used

• Agilent 1260 Infinity Bio-Inert LC (first dimension pump and autosampler)
• Agilent 2D-LC Quick Change Valve with multiple heart-cutting loops (12 × 40 µL)
• Agilent 1290 Infinity high-speed pump (second dimension)
• Agilent Bio-Monolith Protein A column (first dimension)
• Agilent AdvanceBio SEC 300 Å, 4.6 × 150 mm, 2.7 µm column (second dimension)
• Diode array detector (DAD) modules in both dimensions
• Agilent OpenLAB CDS ChemStation with 2D-LC software for method configuration and data acquisition

Methodology

First-dimension capture employs a Bio-Monolith Protein A HPLC column at 0.75 mL/min, loading in 100 mM PBS and eluting with 500 mM acetic acid using a rapid gradient. Eluate fractions are sequestered in multiple heart-cutting loops. The second dimension uses an AdvanceBio SEC column at 0.35 mL/min under isocratic 10 mM PBS (pH 7.4). Automated transfer timings synchronize capture and SEC runs, enabling seamless two-step analysis with a single injection.

Results and Discussion

The combined 2D-LC workflow achieved complete IgG capture and aggregate profiling in under eight minutes. Chromatograms demonstrated clear separation of monomer, dimer, and higher-order aggregates. Heat-stressed IgG samples (65 °C for 24 h) showed elevated aggregate peaks, which were baseline resolved from native species. The method eliminated manual fraction collection and shortened total analysis time compared to standalone methods.

Benefits and Practical Applications

• Single-injection workflow streamlines sample processing and reduces cross-contamination risk
• High throughput supports accelerated bioprocess development and quality control
• Robust capture step ensures removal of matrix interferences prior to SEC analysis
• Accurate aggregate quantification aids formulation screening and stability studies

Future Trends and Opportunities

Integration of mass spectrometry detection in the second dimension could provide simultaneous molecular weight confirmation and impurity profiling. Advances in ultra-high-pressure 2D-LC and novel affinity ligands may further reduce analysis time and improve resolution. Adoption in process analytical technology (PAT) frameworks and regulatory collaboration will drive wider implementation in biopharmaceutical manufacturing.

Conclusion

The Agilent 1290 Infinity 2D-LC solution effectively consolidates Protein A affinity capture and SEC into a unified method, offering rapid, reliable IgG titer and aggregation analysis. This approach enhances laboratory efficiency, data quality, and throughput for biotherapeutic characterization and quality control.

References

• Vanhoenacker G, et al. Analysis of Monoclonal Antibody Digests with the Agilent 1290 Infinity 2D-LC Solution. Agilent Technologies Application Note 5991-2880EN, 2013.
• Lidija U, et al. Rapid Human Polyclonal IgG Quantification Using the Agilent Bio-Monolith Protein A HPLC Column. Agilent Technologies Application Note 5989-9733EN, 2008.
• Duong PT. Agilent Bio-Monolith Protein A Monitors Monoclonal Antibody Titer from Cell Cultures. Agilent Technologies Application Note 5991-2990EN, 2014.